Stress Urinary Incontinence (Female)
Stress urinary incontinence (SUI) is the involuntary leakage of urine with physical exertion, coughing, sneezing, or any activity that raises intra-abdominal pressure. It is the most common type of urinary incontinence, affecting approximately 46% of adult women when defined as any symptoms in the previous year, with prevalence peaking at ~50% among women aged 40 and older.[2] SUI causes significant physical, emotional, and social distress and is a leading driver of gynecologic and urogynecologic referral.
ACP Guideline: The American College of Physicians recommends initiating treatment with pelvic floor muscle training (PFMT) in women with stress, urgency, or mixed urinary incontinence — the first-line approach for SUI is behavioral intervention.[1]
Pathophysiology
SUI occurs when intra-abdominal pressure transiently exceeds urethral closure pressure, allowing urine to escape.[2][3] Two primary mechanisms account for most cases:
Urethral hypermobility Loss of pelvic floor muscular support or vaginal connective tissue prevents the urethra and bladder neck from assuming a stable closed position in response to pressure increases. Weakness of support structures and collagen-dependent tissue damage are central. This is the predominant mechanism in most post-partum and post-menopausal patients.
Intrinsic sphincter deficiency (ISD) Loss of intrinsic urethral mucosal and muscular tone results in poor urethral coaptation and a reduced resting urethral closure pressure (<20–60 cmH₂O depending on criteria). ISD produces more severe leakage, often with minimal provocation, and is associated with prior urethral surgery, radiation, and neurological injury.
In practice, many patients exhibit a combination of both mechanisms.
Risk Factors
| Risk Factor | Notes |
|---|---|
| Vaginal delivery | ~2× risk vs cesarean; risk increases with parity and instrumental delivery |
| Increasing parity | Cumulative effect with each vaginal birth |
| Obesity / elevated BMI | Chronic elevated intra-abdominal pressure; weight loss reduces severity |
| Age and menopause | Estrogen deficiency reduces urethral mucosal coaptation; prevalence peaks 40–60 years |
| White race | Higher prevalence than Black or Hispanic women |
| Pelvic surgery | Hysterectomy disrupts endopelvic fascia and autonomic innervation |
| Conditions raising IAP | Chronic cough, constipation, heavy lifting, high-impact exercise |
| Smoking | Chronic cough; collagen effects |
| Connective tissue disorders | Joint hypermobility syndromes associated with PFD |
Diagnostic Evaluation
History
Key elements to assess:
- Leakage pattern: Predictable with cough, sneeze, Valsalva, exercise, position change
- Severity: Frequency (daily, weekly), volume (small drops vs soaking), pad use and type
- Degree of bother: Drives treatment urgency and goal-setting
- Coexisting symptoms: Urgency, urgency incontinence, incomplete emptying, prolapse symptoms, fecal incontinence, dyspareunia
- Obstetric/surgical history: Deliveries, episiotomies, prior anti-incontinence surgery
- Medication review: Diuretics, α-blockers, anticholinergics, caffeine, alcohol
Physical Examination
| Finding | Significance |
|---|---|
| Vulvovaginal atrophy | Common in postmenopausal women; may worsen symptoms |
| Skin maceration / excoriation | Severity of leakage; hygiene counseling |
| Pelvic organ prolapse | May mask or worsen SUI; assess all three compartments |
| Pelvic floor muscle strength | Baseline for PFMT; assess ability to contract voluntarily |
| Urethral hypermobility | Cotton swab (Q-tip) test — rotation >30° from horizontal indicates hypermobility |
| Urethral diverticulum / fistula | Rule out anatomical causes of leakage |
Urinalysis
Mandatory to exclude UTI, hematuria, glycosuria, and pyuria before attributing symptoms to SUI.[2][3]
Voiding Diary
A 1–3 day fluid intake and voiding diary identifies modifiable factors (total intake, caffeine, nocturnal patterns) and quantifies leakage frequency when history is insufficient.[3]
Cough Stress Test
Patient voids to comfortable fullness (~300 mL), then coughs or Valsalvas forcefully in standing or lithotomy position. Immediate urethral leakage synchronous with the cough confirms SUI. Positive predictive value 78–97%.[2][3]
Postvoid Residual
Performed by catheterization or bladder ultrasound. Important before surgical planning to exclude incomplete emptying.
Urodynamic Testing
Not required before surgery for uncomplicated, pure stress-predominant SUI with a positive cough stress test and PVR <150 mL.[2][6] Basic office evaluation is non-inferior to multichannel urodynamics in this group. Urodynamics are indicated for:
- Mixed incontinence with significant urgency component
- Prior anti-incontinence surgery (failed or new evaluation)
- Neurogenic lower urinary tract dysfunction
- Elevated PVR or voiding dysfunction
- Discordance between symptoms and examination findings
Treatment
Step 1 — Conservative (First-Line)
Pelvic Floor Muscle Training (PFMT)
The cornerstone of first-line management and the ACP-recommended initial treatment for all women with SUI.[1] PFMT involves repeated voluntary pelvic floor contractions taught and supervised by a trained physiotherapist or pelvic health specialist.
Key evidence:
- Cure rates, symptom improvement, satisfaction, and QoL all significantly improved vs control[7][9]
- ~50% of women with stress-predominant incontinence are satisfied at 1 year with supervised PFMT[6]
- More intensive programs with adherence support are more effective than unsupervised instruction[7]
- Clinically successful treatment is defined as ≥50% reduction in incontinence episode frequency[1]
Adjunctive physical therapy modalities:
| Modality | Evidence |
|---|---|
| Biofeedback | PFMT + biofeedback superior to PFMT alone |
| Vaginal cones | Weighted resistance training; modest benefit |
| Electrical stimulation | Benefits quality of life outcomes |
| Intravaginal pessaries | Incontinence ring/dish type; improves QoL; may be combined with PFMT |
Lifestyle Modifications
| Modification | Rationale |
|---|---|
| Weight loss | Even 5–10% reduction improves SUI in overweight/obese women[6][9] |
| Fluid management | Limit total intake to ≤2 L/day; avoid excessive restriction |
| Caffeine reduction | Even 1 cup/day associated with incontinence; trial of elimination warranted |
| Reduce nocturnal fluids | For nocturia-associated symptoms |
| Frequent voiding | Reduce bladder volume at times of activity |
| Constipation management | Reduces chronic Valsalva and pelvic floor strain |
Step 2 — Surgical (Second-Line)
Reserved for patients with inadequate response to conservative therapy, or may be first-line based on severity and patient preference after shared decision-making.
Midurethral Slings (Synthetic Mesh)
The most common primary surgical treatment for female SUI — well-established efficacy data:
| Metric | Midurethral Sling | PFMT (comparison) |
|---|---|---|
| Subjective cure at 1 year | 85% | 53% |
| Objective cure at 1 year | 76.5% | 58.8% |
| Cross-over from PFMT → surgery | 49% at trial completion | — |
| Cross-over from surgery → PFMT | 11% | — |
Compared to other surgical options:[6]
- Equivalent to traditional autologous fascial slings, open Burch colposuspension, and laparoscopic colposuspension in efficacy
- Fewer adverse events than suburethral fascial slings
- Less voiding dysfunction than open colposuspension
Note on mesh: FDA actions (2011, 2019) restricted transvaginal mesh for prolapse but midurethral slings for SUI retain regulatory approval given favorable risk-benefit data. Mesh-related concerns have increased patient hesitancy; informed discussion is essential.[8]
Types of midurethral slings:
| Type | Approach | Notes |
|---|---|---|
| Retropubic (TVT) | Behind pubic bone | Highest long-term data; bladder injury risk ~3–5% |
| Transobturator (TOT/TVT-O) | Lateral obturator | Lower bladder injury risk; higher groin/thigh pain rate |
| Single-incision mini-sling | Anchored midurethral | Shorter procedure; long-term data still maturing |
Autologous Fascial Sling
Pubovaginal sling using rectus fascia or fascia lata. Established robust evidence; preferred when mesh is contraindicated or patient declines synthetic materials. Higher voiding dysfunction rate than midurethral slings; durable long-term results.[8][9]
Burch Colposuspension
Open or laparoscopic retropubic colposuspension (paravaginal sutures to Cooper's ligament). Equivalent to midurethral sling in appropriately selected patients. Particularly applicable at the time of abdominal sacrocolpopexy — concurrent Burch reduces de novo post-operative SUI.[6]
Urethral Bulking Agents
Periurethral or transurethral injection of bulking material (polyacrylamide hydrogel, calcium hydroxylapatite, dextranomer/hyaluronic acid). Office-based, minimally invasive option. Lower cure rates than slings; useful in patients unfit for anesthesia, prior mesh failure, ISD-predominant disease, or as temporizing measure.[8]
Artificial Urinary Sphincter
Reserved for severe, complicated SUI — particularly ISD after prior failed surgery or radiation. High-quality data limited for this indication in women; see AUS article.[6]
Pharmacotherapy
Medical therapies for SUI are generally not recommended — current evidence-based pharmacological treatments primarily address urgency incontinence (antimuscarinics, β3-agonists), not SUI.[6]
Duloxetine (SNRI, not FDA-approved for SUI in the US) has modest evidence for symptom improvement but significant side effects limiting use; not in routine clinical practice in North America.
Emerging Therapies
Vaginal laser therapy (CO₂ fractional laser, Er:YAG laser) has been investigated for SUI. A 2025 Cochrane review (Ippolito et al.) provides updated evidence; this remains an evolving area without established guideline support.[5]
Outcomes
| Treatment | Expected Outcome |
|---|---|
| PFMT (supervised) | ~50% satisfaction at 1 year; best with early initiation and professional supervision |
| Midurethral sling | 85% subjective cure, 76.5% objective cure at 1 year |
| Burch colposuspension | Equivalent to MUS; ~80% success at 1 year |
| Autologous fascial sling | Durable; ~85% success; higher voiding dysfunction rate |
| Bulking agents | 50–60% short-term improvement; lower durability |
Clinical Approach Summary
Recommended stepwise approach for a woman presenting with SUI:
- Assess bother and QoL impact — drives urgency and goals of treatment
- Quantify leakage — frequency, volume, pad use, pad weight test if available
- Pelvic exam — prolapse assessment, muscle function, Q-tip test, cough stress test
- Urinalysis — rule out UTI
- First-line: Prescribe supervised PFMT ± lifestyle modifications (weight loss, caffeine reduction)
- Adjuncts: Incontinence pessary if patient prefers non-surgical option or awaits PFMT response
- Persistent symptoms: Refer with shared decision-making re: sling vs colposuspension vs bulking; obtain PVR ± urodynamics per complexity
Referral Indications
- Significant pelvic organ prolapse (concurrent repair consideration)
- Elevated PVR / voiding dysfunction
- Failed prior anti-incontinence surgery
- Mixed incontinence with dominant urgency component
- Consideration of surgical management
- Neurological comorbidity
References
- Qaseem A, Dallas P, Forciea MA, et al. Nonsurgical management of urinary incontinence in women: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2014;161(6):429–40. PMID 25222388
- Wu JM. Stress incontinence in women. N Engl J Med. 2021;384(25):2428–36. PMID 34133856
- Lukacz ES, Santiago-Lastra Y, Albo ME, Brubaker L. Urinary incontinence in women: a review. JAMA. 2017;318(16):1592–1604. PMID 29067433
- Ayeleke RO, Hay-Smith EJ, Omar MI. Pelvic floor muscle training added to another active treatment versus the same active treatment alone for urinary incontinence in women. Cochrane Database Syst Rev. 2015;(11):CD010551. PMID 26558551
- Ippolito GM, Crescenze IM, Sitto H, et al. Vaginal lasers for treating stress urinary incontinence in women. Cochrane Database Syst Rev. 2025;7:CD013643. doi:10.1002/14651858.CD013643.pub2
- ACOG Practice Bulletin No. 155: Urinary incontinence in women. Obstet Gynecol. 2015;126(5):e66–81. PMID 26488524
- Todhunter-Brown A, Hazelton C, Campbell P, et al. Conservative interventions for treating urinary incontinence in women: an overview of Cochrane systematic reviews. Cochrane Database Syst Rev. 2022;9:CD012337. PMID 36047951
- Moris L, Heesakkers J, Nitti V, et al. Prevalence, diagnosis, and management of stress urinary incontinence in women: a collaborative review. Eur Urol. 2025;87(3):292–301. PMID 39743413
- O'Reilly N, Nelson HD, Conry JM, et al. Screening for urinary incontinence in women: a recommendation from the Women's Preventive Services Initiative. Ann Intern Med. 2018;169(5):320–28. PMID 30105373